2021 Global Conference Coverage: An Update on the Clinical Development Across Gynecologic Malignancies*

In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, discuss new data for gynecologic cancers presented at the virtual ASCO 2021 annual meeting, including novel data for single-agent immunotherapy in patients with endometrial cancer, data for novel agents targeting the folate receptor-α in ovarian cancer, and data for a novel bifunctional fusion proteins cotargeting the TGF-β receptor and PD-L1 pathways in cervical cancers.

Melissa M. Hardesty, MD, MPH David Scott Miller, MD, FACOG, FACS Released: June 24, 2021

In this podcast episode, listen to Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, discuss important new clinical trial data for endometrial and ovarian cancers presented at the virtual ESMO 2021 annual meeting.

Bernard Doger de Spéville, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Released: September 29, 2021

In this podcast episode, listen to Nicole Concin, MD, PhD, as she highlights important clinical trial data for ovarian and endometrial cancers presented at the ESGO 2021 annual meeting.

Nicole Concin, MD, PhD Released: November 23, 2021

In this podcast episode, listen to Ursula Matulonis, MD, and Jubilee Brown, MD, discuss new data for gynecological cancers presented at the virtual SGO 2021 meeting, including immunotherapy-based combinations for endometrial cancer and PARP inhibitors for BRCA-mutated ovarian cancers.

This podcast is intended for clinicians practicing medicine outside of the United States.

Jubilee Brown, MD Ursula Matulonis, MD Released: April 7, 2021

In this podcast episode, listen to Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, discuss practice‑changing data for gynecologic cancers presented at the virtual IGCS 2021 annual meeting, including novel data for single-agent and combination immunotherapy in patients with endometrial and cervical cancers, subanalyzes of exceptional responders to PARP inhibitors in ARIEL3, and timing for initiation of PARP inhibitor maintenance from the NORA trial.

Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Released: September 21, 2021